AbbVie vs Bristol Myers Squibb
Established biopharmaceutical company with strong cash flow vs Diversified biopharmaceutical company with oncology and immunology medicines. Which is the better buy for your portfolio in July 2026? Plain-English answer below.
AbbVie built an empire on Humira and is now sprinting to diversify its immunology and oncology pipeline before biosimilar erosion bites, while Bristol Myers Squibb has assembled a formidable cancer drug franchise anchored by Opdivo and Eliquis. Both pharma giants are navigating the same brutal patent cliff cycle and deploying billions in M&A to replenish revenue. AbbVie vs Bristol Myers Squibb puts two of the industry's biggest cash-flow machines side by side to compare their pipeline depth, dividend sustainability, and long-term growth bets.
AbbVie built an empire on Humira and is now sprinting to diversify its immunology and oncology pipeline before biosimilar erosion bites, while Bristol Myers Squibb has assembled a formidable cancer dr...
Why It’s Moving
AbbVie stays in the spotlight as Wall Street’s bullish consensus keeps debate alive.
- Analyst sentiment remains broadly constructive, with most recent consensus readings still clustered around Buy or Moderate Buy, keeping the stock in focus as investors weigh whether Wall Street’s optimism is justified.
- The latest price-target ranges remain wide, which suggests the market is still debating how much of AbbVie’s growth and pipeline strength is already priced in versus what could still surprise to the upside.
- Near-term moves are likely being driven more by analyst revisions and expectations around future earnings than by a single fresh catalyst, so the stock is reacting to changing conviction rather than a new company event.
BMY slips into analyst caution as slowing growth expectations keep upside capped
- Wall Street’s latest read on Bristol-Myers Squibb is cautious: the consensus has shifted toward “Hold,” signaling that analysts see limited near-term catalyst strength and are weighing the company’s pipeline against slower growth expectations.
- The stock is being pressured by a softer revenue outlook, with analysts pointing to possible contraction over the next year; that raises concerns that existing products may not be enough to offset patent-related headwinds and slower expansion.
- Recent analyst updates suggest valuation is no longer being treated as an automatic bargain, as lower growth assumptions and mixed ratings have narrowed the gap between the stock’s current price and Wall Street’s average view.
AbbVie stays in the spotlight as Wall Street’s bullish consensus keeps debate alive.
- Analyst sentiment remains broadly constructive, with most recent consensus readings still clustered around Buy or Moderate Buy, keeping the stock in focus as investors weigh whether Wall Street’s optimism is justified.
- The latest price-target ranges remain wide, which suggests the market is still debating how much of AbbVie’s growth and pipeline strength is already priced in versus what could still surprise to the upside.
- Near-term moves are likely being driven more by analyst revisions and expectations around future earnings than by a single fresh catalyst, so the stock is reacting to changing conviction rather than a new company event.
BMY slips into analyst caution as slowing growth expectations keep upside capped
- Wall Street’s latest read on Bristol-Myers Squibb is cautious: the consensus has shifted toward “Hold,” signaling that analysts see limited near-term catalyst strength and are weighing the company’s pipeline against slower growth expectations.
- The stock is being pressured by a softer revenue outlook, with analysts pointing to possible contraction over the next year; that raises concerns that existing products may not be enough to offset patent-related headwinds and slower expansion.
- Recent analyst updates suggest valuation is no longer being treated as an automatic bargain, as lower growth assumptions and mixed ratings have narrowed the gap between the stock’s current price and Wall Street’s average view.
Investment Analysis
AbbVie
ABBV
Pros
- AbbVie maintains dominant market position in immunology with Skyrizi and Rinvoq driving robust revenue growth.
- Strong balance sheet supports sustained R&D investment and share repurchases amid patent cliffs.
- Humira successors demonstrate high-teens growth potential offsetting legacy product declines.
Considerations
- Ongoing patent expirations for key drugs expose revenue to generic erosion through 2028.
- Regulatory hurdles in obesity portfolio delay potential new growth catalysts.
- High debt levels from past acquisitions elevate financial risk in rising interest environment.
Pros
- Growth products like Eliquis, Reblozyl and Breyanzi deliver strong double-digit sales increases into 2026.
- Attractive 4.5% dividend yield backed by 56-year payment history and recent hikes.
- Pipeline catalysts in 2026 offer substantial upside potential beyond priced-in LOE headwinds.
Considerations
- Legacy portfolio faces 15-17% revenue decline in 2025 from generic competition.
- Loss of exclusivity pressures persist through 2028 with $20-30 billion revenue impact.
- Sell-side consensus holds 'Hold' rating despite recent upgrades amid execution uncertainties.
AbbVie (ABBV) Next Earnings Date
AbbVie’s next earnings date is expected on July 30–31, 2026, with multiple market sources pointing to July 31, 2026 before the market opens. The report will cover Q2 2026 results. This date is consistent with AbbVie’s typical late-July earnings pattern.
Bristol Myers Squibb (BMY) Next Earnings Date
Bristol Myers Squibb (BMY) is scheduled to report its next earnings on July 30, 2026. The release will cover second-quarter 2026 results. The company has also indicated the announcement will be made before the market opens, with a conference call later that morning.
AbbVie (ABBV) Next Earnings Date
AbbVie’s next earnings date is expected on July 30–31, 2026, with multiple market sources pointing to July 31, 2026 before the market opens. The report will cover Q2 2026 results. This date is consistent with AbbVie’s typical late-July earnings pattern.
Bristol Myers Squibb (BMY) Next Earnings Date
Bristol Myers Squibb (BMY) is scheduled to report its next earnings on July 30, 2026. The release will cover second-quarter 2026 results. The company has also indicated the announcement will be made before the market opens, with a conference call later that morning.
Buy ABBV or BMY in Nemo
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
